Understanding Relapsed and Refractory Blood Cancers: Treatment Options and Strategies

Blood cancers—also known as hematologic malignancies—are a significant global health concern, with approximately 1.34 million new cases diagnosed worldwide in 2019, accounting for about 6% of all cancer cases. These cancers include multiple myeloma, leukemia, and lymphoma, which affect the blood, bone marrow, and lymphatic system. While many patients achieve remission with initial treatments, a substantial proportion experience relapse or develop refractory disease, meaning their cancer returns or no longer responds to standard therapies.

Relapsed and refractory blood cancers pose a significant challenge in oncology, requiring specialised treatment strategies.  In response, cutting-edge therapies—including combination regimens, targeted drugs, immunotherapy, and CAR-T cell therapy—are revolutionising outcomes for patients who previously had limited options.

This blog explores the complexity of blood cancer treatment, why these cancers relapse, including combination therapies meant to overcome treatment resistance and the latest breakthroughs that offer renewed hope for patients facing relapsed or refractory disease.

What Are Relapsed and Refractory Blood Cancers?

Relapsed Blood Cancers: Blood cancer that recurs after a period of remission is known as relapsed blood cancer. The term "remission" describes the absence of cancer cells after treatment. Relapse could result from any malignant cells that remain and multiply.

Refractory Blood Cancers: Blood malignancies classified as refractory occur when the disease advances in spite of treatment or does not react to common treatments. In certain cases, cancer cells show signs of resistance to targeted therapy, immunotherapy, or traditional chemotherapy.

Both relapsed and refractory hematologic malignancies require aggressive treatment modifications and personalised therapeutic strategies to improve patient outcomes.

Why Do Blood Malignancies Relapse or Become Refractory?

Blood malignancies can relapse or become refractory due to various biological reasons. These include genetic mutations, changes in the tumour microenvironment, and therapeutic pressure. Below are the key reasons:

1. Genetic Mutations

Over time, cancer cells develop genetic mutations that cause tumours to become therapy-resistant. Like in acute myeloid leukaemia (AML), mutations in FLT3, TP53, or NRAS may develop after initial treatment, making the disease more difficult to control.

2. Drug Resistance Mechanisms

Some cancer cells develop resistance to chemotherapy by using tiny pumps on their surface to push the drug out before it can work. These pumps, like P-glycoprotein (MDR1), BCRP, and MRP1, act like "bouncers," kicking the drug out of the cell and making treatment less effective. Thus, cancer cells survive and continue to grow despite the medications.

3. Tumor Microenvironment Protection

The bone marrow acts like a safe house for cancer cells. Support cells in the bone marrow send survival signals (like IL-6 in multiple myeloma) that help cancer cells hide from chemotherapy. Some cancer cells even go into sleep mode, making them harder to kill. Later, they can "wake up" and cause the cancer to return.

4. Minimal Residual Disease (MRD) and Dormant Cells

Even when a patient appears to be in remission, small numbers of undetectable cancer cells (MRD-positive) can remain in the body. These cells can later regrow and cause a relapse.

5. Immune System Evasion

Blood cancers can trick the immune system to avoid being attacked. Some cancer cells increase PD-L1 expression, which acts like a "stop sign" that prevents immune cells (T-cells) from attacking them.

6. Suboptimal Drug Exposure

Some cancer cells hide in protected areas like the brain or spinal cord, where chemotherapy can’t reach them well (e.g., in leukaemia). Also, if the body breaks down or clears the drug too quickly, the medicine may not be strong enough to kill all cancer cells, allowing resistant ones to survive and grow.

Blood cancers relapse or become refractory due to genetic changes, drug resistance, and immune evasion. Targeted therapies and advanced treatments are key to overcoming these challenges.

Navigating Treatment Options for Relapsed and Refractory Blood Cancers

A specialised treatment strategy is required when blood cancer recurs (relapses) or becomes resistant, meaning it no longer responds to therapy. Factors like the type of cancer, length of remission, prior treatments, and general health all influence the therapy selection. In order to control the disease over the long term, the objective is to attain a second remission and, if feasible, move forward with more aggressive treatments like stem cell transplantation. 

The main therapies for relapsed or refractory blood malignancies are listed below:

1. Chemotherapy

Chemotherapy remains a key treatment option for relapsed or refractory blood cancers, even if the initial regimen was unsuccessful.  In order to overcome resistance, many chemotherapy medications or combinations may still be helpful.   

These drugs kill rapidly proliferating cancer cells by either destroying their DNA or interfering with their ability to divide. To defeat resistant cancer cells, oncologists frequently choose novel drug combinations. 

Common salvage chemotherapy regimens include:

• R-ICE (Rituximab, Ifosfamide, Carboplatin, and Etoposide) or R-DHAP (Rituximab, Dexamethasone, Cytarabine, and Cisplatin) for lymphoma 
• FLAG-IDA (Fludarabine, Cytarabine, G-CSF, and Idarubicin) for leukaemia
• KRd (Carfilzomib, Lenalidomide, and Dexamethasone) for multiple myeloma. 

The goal of these treatments is to bring about a second remission and possibly get patients ready for more curative procedures like stem cell transplantation. 

2. Targeted Therapy

Targeted therapies are more accurate and less harmful than chemotherapy because they target particular genetic variations or pathways that contribute to the growth of cancer. 

• Imatinib and dasatinib are examples of tyrosine kinase inhibitors (TKIs) that block abnormal proteins in chronic myeloid leukaemia and acute lymphoblastic leukaemia.
• Venetoclax and BCL-2 inhibitors accelerate the death of cancer cells in AML and CLL..
• Protease inhibitors (carfilzomib, boratezamib) interfere with the breakdown of proteins in multiple myeloma, which results in the death of cancer cells.

These treatments decrease the negative effects and increase treatment accuracy.

3. Immunotherapy

Immunotherapy is an advanced cancer treatment that improves the immune system's ability to recognise and destroy malignant cells. It boosts the body's natural defences, making it an effective treatment for blood cancers that have relapsed or are refractory.

Types of Immunotherapy:

• Checkpoint Inhibitors: Checkpoint proteins like PD-L1 and CTLA-4 enable cancer cells to "hide" from the immune system by inhibiting immunological responses. By inhibiting these proteins, checkpoint inhibitors improve the immune system's ability to identify and eliminate cancer cells.
• CAR T-cell Therapy: This treatment involves collecting the patient's T cells—a kind of immune cell—and modifying them genetically in the laboratory to identify particular cancer markers. Then, the cells are reinfused into the patient. These CAR T cells help in identifying and eliminating cancer cells. For patients with blood malignancies that have relapsed after several therapies, CAR T-cell therapy has demonstrated impressive results.

Immunotherapy enhances the immune system to fight relapsed or refractory blood cancers. Key approaches include checkpoint inhibitors, which unblock immune responses, and CAR T-cell therapy, which genetically modifies T cells to target cancer cells effectively.

4. Bispecific Antibodies

These antibodies are specifically developed to bind to immune cells (T cells) and cancer cells simultaneously. This "double binding" effect helps the immune system recognise and attack cancer more efficiently, even when it struggles to do so naturally. Immunotherapy provides long-lasting responses, especially in relapsed cancers, with some patients achieving durable remissions for years.

5. Stem Cell Transplantation (SCT)

Stem Cell Transplantation (SCT), sometimes referred to as a bone marrow transplant, replaces damaged bone marrow with healthy stem cells. 

There are two main types: 

• Autologous stem cell transplant: In this, the patient's own stem cells are extracted before high-dose chemotherapy.
• Allogeneic Stem Cell Transplant: In this, the patient receives healthy stem cells from a donor instead of using their own.

6. Combination Therapy for Refractory Lymphoma

Combination therapy for refractory lymphoma refers to using multiple treatments—such as from Chemotherapy to Radiation Therapies, immunotherapy, targeted therapy, or cellular therapy—to improve outcomes in patients whose lymphoma does not respond to standard treatments.

 

Emerging Therapies for Relapsed and Refractory Blood Cancers

Advanced therapies for recurrent hematologic malignancies are expected to concentrate on the following:

• Using gene editing (CRISPR-based treatments) to target cancer cells precisely.
• CAR-T and NK-cell treatments of the next generation to increase effectiveness and lessen negative effects.
• Personalised medicine techniques use genomes and artificial intelligence to customise care for every patient.

The future of treating leukaemia/lymphoma that is resistant to treatment depends on a multidisciplinary strategy that combines next-generation targeted therapies, immunotherapy, and precision medicine.

Advancing Toward Better Outcomes

Managing relapsed and refractory blood cancers requires innovative treatment strategies tailored to each patient’s unique disease characteristics. From salvage therapy in blood cancers to novel targeted treatments for relapsed leukaemia, the evolving landscape of therapies provides hope for patients facing treatment resistance.

Breakthroughs in combination therapy for refractory lymphoma,  CAR-T therapy, and immunotherapy continue to reshape survival outcomes, emphasising the need for ongoing research and clinical advancements in hematologic malignancies.